Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | RCE1 | Q9Y256 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26207778 | 0.92 | MAPT (0.38) | MAPTMEN1KMT2AKDM4EHTT | |
| SCHEMBL4975848 | 0.77 | PTGDR2 (0.47) | KDM4EHTTMDM2ALDH1A1LMNA | |
| SCHEMBL4982011 | 0.76 | KMT2A (0.44) | MAPTMEN1KMT2AKDM4EHTT | |
| SCHEMBL9750249 | 0.76 | KMT2A (0.39) | MAPTMEN1KMT2AKDM4EHTT | |
| SCHEMBL14440502 | 0.73 | KMT2A (0.41) | MAPTMEN1KMT2AKDM4EHTT | |
| SCHEMBL14428040 | 0.72 | KMT2A (0.40) | MAPTMEN1KMT2AKDM4EHTT | |
| SCHEMBL19116479 | 0.71 | KMT2A (0.42) | MAPTMEN1KMT2AKDM4EHTT | |
| SCHEMBL14428033 | 0.71 | — | — | |
| SCHEMBL5007535 | 0.71 | MDM2 (0.37) | MDM2ALDH1A1LMNAPOLBSMN1; SMN2 | |
| SCHEMBL4603835 | 0.71 | KMT2A (0.53) | MAPTMEN1KMT2AKDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382857-A1 | HEPTAMETHINE CYANINES FOR USE AS FLUORESCENT MARKERS OF THE BILIARY AND RENAL SYSTEMS | CHILDREN'S NATIONAL MEDICAL CENTER (US) | 2023-11-30 | — | — | US | disclosed |
| US-11787764-B2 | Heptamethine cyanines for use as fluorescent markers of the biliary and renal systems | CHILDREN'S NATIONAL MEDICAL CENTER (US) | 2023-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787764-B2 | Heptamethine cyanines for use as fluorescent markers of the biliary and renal systems | CD68, PAX2, PYGL | MAPT 3283/4885MEN1 512/4885KMT2A 2922/4885 |
| US-20230382857-A1 | HEPTAMETHINE CYANINES FOR USE AS FLUORESCENT MARKERS OF THE BILIARY AND RENAL SYSTEMS | CD68, HCCS, NR1H4 | MAPT 3765/4885MEN1 572/4885KMT2A 3008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.